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Abstract. 
 
Guanine nucleotide exchange factors (GEFs)
activate Ras by facilitating its GTP binding. Ras guanyl
nucleotide-releasing protein (GRP) was recently iden-
tiﬁed as a Ras GEF that has a diacylglycerol (DAG)-
binding C1 domain. Its exchange factor activity is
regulated by local availability of signaling DAG. DAG
kinases (DGKs) metabolize DAG by converting it to
phosphatidic acid. Because they can attenuate local ac-
cumulation of signaling DAG, DGKs may regulate Ras-
GRP activity and, consequently, activation of Ras.
 
DGK
 
z
 
, but not other DGKs, completely eliminated
Ras activation induced by RasGRP, and DGK activity
was required for this mechanism. DGK
 
z
 
 also coimmu-
noprecipitated and colocalized with RasGRP, indicat-
ing that these proteins associate in a signaling complex.
Coimmunoprecipitation of DGK
 
z
 
 and RasGRP was
enhanced in the presence of phorbol esters, which are
DAG analogues that cannot be metabolized by DGKs,
suggesting that DAG signaling can induce their interac-
tion. Finally, overexpression of kinase-dead DGK
 
z
 
 in
Jurkat cells prolonged Ras activation after ligation of
the T cell receptor. Thus, we have identiﬁed a novel way
to regulate Ras activation: through DGK
 
z
 
, which con-
trols local accumulation of DAG that would otherwise
activate RasGRP.
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Introduction
 
DAG is a lipid second messenger that transiently accumu-
lates after activation of growth factor receptors and other
receptors (Bishop and Bell, 1986). In these cases, for an ap-
propriate cellular response, DAG signaling is necessary
but must be short-lived since persistently high DAG levels
induce malignant transformation. Experimentally, trans-
formation caused by abnormally prolonged DAG signaling
has been demonstrated by either overexpressing PLC iso-
forms (Chang et al., 1997; Nebigil, 1997) which generate
DAG, or in studies using the phorbol esters, which are po-
tent tumor promoters. Phorbol esters, like DAG, bind to
DAG-responsive C1 domains (Kazanietz et al., 1994) and
since they are very slowly metabolized, they mimic a sus-
tained DAG signal. Their transforming activity has been
attributed most often to persistent activation of PKC iso-
forms, which clearly are involved (Housey et al., 1988; Ron
and Kazanietz, 1999). However, PKCs are not the only
proteins allosterically activated by DAG; several proteins,
 
including Ras guanyl nucleotide-releasing protein (GRP),
 
1
 
the chimaerins, Unc-13, and protein kinase D (Hurley et
al., 1997; Ron and Kazanietz, 1999) have C1 domains and
can bind and are activated by DAG or phorbol esters.
RasGRP was identified as a guanine nucleotide ex-
change factor (GEF) that is specific for Ras (Ebinu et
al., 1998; Kawasaki et al., 1998; Tognon et al., 1998).
 
DAG is necessary for its function; without its DAG-
responsive C1 domain, RasGRP no longer activates
Ras. This was demonstrated in two studies using either
Rat2 or NIH 3T3 cells, where a C1 deletion mutant of
RasGRP was not transforming, even in the presence of
high concentrations of phorbol ester, whereas wild-type
RasGRP induced morphologic transformation at much
lower phorbol ester concentrations (Ebinu et al., 1998;
Tognon et al., 1998). This suggests that in some cases,
RasGRP participates in cell transformation induced by
phorbol esters or sustained DAG signaling. Thus, condi-
tions inducing abnormally active RasGRP may contrib-
ute to tumor formation. Supporting this, Li et al. (1999),
using large scale insertional mutagenesis, recently iden-
tified RasGRP as a potential leukemia disease gene. It is
important then that cells regulate the DAG that acti-
vates RasGRP. This must occur through precise, spatial
metabolism of the signaling DAG. We considered this
possibility and hypothesized that DGKs which convert
DAG to phosphatidic acid (PA; Sakane and Kanoh,
1997; Topham and Prescott, 1999) serve as an “off”
mechanism for RasGRP.
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We demonstrate here that DGK activity inhibits Ras-
GRP. This regulation appears to be selective and spatially
discrete: only one of six DGK isotypes, DGK
 
z
 
, inhibited
RasGRP. Consistent with this regulation occurring in a sig-
naling complex, we observed that DGK
 
z
 
 associated with
both RasGRP and H-Ras and that it colocalized with Ras-
GRP in a glioblastoma cell line. Additionally, overexpres-
sion of a kinase-dead DGK
 
z
 
 prolonged Ras activation after
ligation of the T cell receptor (TCR) in Jurkat cells, indicat-
ing that RasGRP is regulated by DGK
 
z
 
 in vivo. This regu-
lation likely occurs through spatial metabolism of signaling
DAG and may represent a general mechanism in which a
DGK associates with a protein activated by DAG and reg-
ulates its activity through its DGK enzymatic function.
 
Materials and Methods
 
Expression Plasmids
 
Wild-type, and V12- and A15-H-Ras in pEF-Myc were a gift from Dr. An-
drew Thorburn (University of Utah). Human DGKs 
 
b
 
, 
 
g
 
, and 
 
d
 
 in pSRE
were a gift from Dr. Fumio Sakane (Sapporo Medical University, Sap-
poro, Japan). Cloning of human DGKs 
 
e
 
, 
 
z
 
2, and 
 
i
 
 has been published pre-
viously (Topham and Prescott, 1999). Human lysosomal acid lipase/cho-
lesterol ester hydrolase (HLAL), a DAG lipase, was cloned from a human
endothelial cell library (a gift from Evan Sadler, Washington University,
St. Louis, MO) and then subcloned into pCDNA1 (Invitrogen). A FLAG
epitope tag was placed at the COOH terminus of full-length DGK
 
z
 
 by
creating a unique EcoRI site (Quickchange mutagenesis kit; Stratagene)
using the oligonucleotide (5
 
9
 
-GAGGACCAGGAGAATTCTGTGTAG-
3
 
9
 
) and its complement. The FLAG tag was then inserted by digesting the
cDNA with EcoRI and then ligating the annealed sense and antisense oli-
gonucleotides encoding the FLAG epitope tag as described previously
(Topham et al., 1998). Progressive COOH-terminal deletions of DGK
 
z
 
were generated by digesting the above plasmid with EcoRI and either
BsaBI (amino acids 1–748), HindIII (amino acids 1–605), or XhoI (amino
acids 1–467) and then a FLAG epitope tag was ligated as above. NH
 
2
 
-ter-
minal hemagglutinin (HA) epitope tags were placed onto DGKs 
 
b
 
, 
 
g
 
, 
 
d
 
, 
 
e
 
,
 
z
 
, and 
 
i
 
 by cloning the full-length DGK into pHA-cytomegalovirus (CMV;
CLONTECH Laboratories, Inc.). A plasmid encoding human RasGRP
was constructed by combining two EST clones (EMBL/GenBank/DDBJ
accession nos. Z41118 and AA283882) and a PCR product isolated from
A172 cell cDNA using the oligonucleotides 5
 
9
 
-GATGCAGATG-
GAAACCTGTGTC-3
 
9
 
 and 5
 
9
 
-GTGGCTTTGAAGGTGTTAGTGG-3
 
9
 
.
The clone was then ligated in frame into the XhoI-HindIII–digested
pEGFP-C3 vector (CLONTECH Laboratories, Inc.) or pHA-CMV
(CLONTECH Laboratories, Inc.) digested with NotI. A second HA
epitope tag was subsequently ligated into the pHA-CMV construct using
oligonucleotides as described above. The C1 domain of RasGRP was re-
moved by digesting green fluorescent protein (GFP)-RasGRP with XcmI
and then religating the cDNA, or a point mutation (C506G) was created
in its C1 domain using site-directed mutagenesis (Stratagene) with the oli-
gonucleotide 5
 
9
 
-GAAGCCCACTTTTGGTGACAACTGTGC-3
 
9
 
 and its
complement.
 
Cell Lines and Transfection
 
A172, Cos-7, and HEK293 cells were cultured and transfected as de-
scribed (Bunting et al., 1996; Topham et al., 1998). Jurkat cells were
purchased from the American Type Culture Collection and cultured ac-
cording to their instructions. Jurkat cells (10
 
7
 
) were transfected by elec-
troporation with 2 
 
m
 
g myc-Ras and 10 
 
m
 
g GFP or kinase-dead DGK
 
z
 
 us-
ing a Gene Pulser (Bio-Rad Laboratories) at 220 V and a capacitance of
960 microfarads in Opti-MEM (Life Technologies). After 20 min of recov-
ery, the cells were transferred to 10 ml growth medium and then assayed
at 48 h.
 
Antibodies and Immunofluorescence
 
Two peptides (EEFQELVKAKGEELHC and CGVSPKPDPKTIS-
KHVQ) corresponding to human RasGRP were synthesized, conjugated
to keyhole limpet hemocyanin, and injected into rabbits. The antibodies
 
were purified from serum using their affinity peptides. Their specificity
was verified by Western blotting extracts from cells transfected with HA-
RasGRP. Affinity-purified anti-RasGRP (EEFQ) or affinity-purified
anti-DGK
 
z 
 
(Topham et al., 1998) was directly conjugated with Oregon
green 514 (anti-RasGRP) or Texas red X (anti-DGK
 
z
 
) using protein la-
beling kits (Molecular Probes).
Indirect immunofluorescent staining of A172 cells was performed as
described previously (Topham et al., 1998), using either anti-DGK
 
z
 
(1:100) or anti-RasGRP (EEFQ, 1:200). To stain actin, Texas red phalloi-
din (1:200; Molecular Probes) was added with the secondary antibody. To
verify the specificity of immunostaining, two volumes of an affinity
peptide (1 mg/ml) were preincubated with one volume of the antibodies
(0.7–1.0 mg/ml) for 
 
.
 
1 h on ice before immunostaining. For direct immu-
nofluorescence to simultaneously detect both RasGRP and DGK
 
z
 
, the
same protocol was used, except that the directly conjugated antibodies,
each diluted at 1:50, were combined and incubation of the secondary anti-
body and phalloidin was omitted.
 
Immunoprecipitation
 
DGK
 
z
 
-FLAG, V12- or A15-H-Ras, HA-RasGRP, or control plasmids
were transfected into HEK293 or Cos-7 cells (500 ng each construct). 48 h
later, cells were harvested in IP buffer (50 mM Hepes, pH 7.4, 150 mM
NaCl, 5 mM MgCl
 
2
 
, 1% NP-40, 1 mM DTT, 1 mM PMSF, 0.5 mM sodium
orthovanadate, and 10 mg/ml each leupeptin, pepstatin, aprotinin, and
soybean trypsin inhibitor), allowed to lyse for 10 min, and then centri-
fuged to remove debris. To immunoprecipitate DGK
 
z
 
, 25 
 
m
 
l monoclonal
anti-FLAG M2 (Sigma-Aldrich) or normal mouse IgG (Santa Cruz Bio-
technology, Inc.) coupled to agarose beads were added to the superna-
tants. After incubating for 2 h (4
 
8
 
C), the beads were washed with TBSTM
(50 mM Tris, pH 7.5, 250 mM NaCl, 0.1% Tween 20, and 5 mM MgCl
 
2
 
)
once, IP wash (50 mM Hepes, pH 7.5, 100 mM NaCl, 0.1% Triton X-100,
10% glycerol, 5 mM MgCl
 
2
 
, and 20 mM NaF) three times, and 5 mM
MgCl
 
2
 
 in H
 
2
 
O once. The beads were then used for SDS-PAGE. Anti-Ras
(C-20; Santa Cruz Biotechnology, Inc.) was used to immunoblot for
H-Ras; anti-RasGRP (EEFQ or CGVS) or anti-HA (CLONTECH Labo-
ratories, Inc.) was used to detect RasGRP; and DGK
 
z
 
 was detected with
an antibody described previously (Bunting et al., 1996). To immunopre-
cipitate HA-RasGRP from transfected cells, the cell lysates were pre-
cleared with agarose-coupled protein G (30 
 
m
 
l; Pierce Chemical Co.) and
then monoclonal anti-HA (F-7, 10 
 
m
 
l; Santa Cruz Biotechnology, Inc.)
was added to the supernatants. After 1 h (4
 
8
 
C), 20 
 
m
 
l protein G was added
followed by a 1-h incubation (4
 
8
 
C). The agarose beads were washed twice
with Mg
 
2
 
1
 
-containing lysis buffer (Taylor and Shalloway, 1996), twice
with IP wash, and then used for SDS-PAGE. To immunoprecipitate en-
dogenous RasGRP from A172 cells, anti-RasGRP (10 
 
m
 
l of either EEFQ
or CGVS, 1.0 mg/ml) preincubated with affinity peptide or control pep-
tide, as described in the immunostaining protocol, was added to pre-
cleared A172 lysates and incubated overnight at 4
 
8
 
C. Protein A/G–aga-
rose (25 
 
m
 
l; Santa Cruz Biotechnology, Inc.) was then added for 1 h at 4
 
8
 
C.
The complex was washed with IP wash three times and then used for
DGK assays or Western blotting as described (Topham et al., 1998).
 
Elk-1 Luciferase Assay
 
PKC inhibitors were from Calbiochem. Elk-1 activity was determined us-
ing the Elk-1 luciferase reporter system (Stratagene) according to the
manufacturer’s instructions with two modifications. First, HA-DGK or
human lysosomal acid lipase/cholesterol ester hydrolase (HLAL) (75–150
ng), GFP-RasGRP (150 ng), V12-Ras (50 ng), MEK1 (50 ng), Raf:ER
(400 ng), or 
 
b
 
-galactosidase (200 ng) cDNA constructs or control vectors
were added to experimental points. Second, the HEK293 cells were main-
tained in medium with 0.5% serum throughout the experiment. Luciferase
activity (Promega) was normalized to 
 
b
 
-galactosidase activity (Tropix).
Similar results were obtained when luciferase activity was normalized to
total protein in the lysates. DGK activity levels and total DAG and lipid
phosphate were also determined in appropriate lysates as described previ-
ously (Bunting et al., 1996; Topham et al., 1998), except that the reactions
contained 2 mM CaCl
 
2
 
 and 1-stearoyl-2-arachidonoyl DAG was used as
the substrate.
 
Affinity Precipitation of GTP-Ras from
Cell Homogenates
 
To measure changes in GTP-Ras induced by a DGK in HEK293 cells, the
cells were transfected with GFP or GFP-RasGRP (300 ng), myc-Ras (100 
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ng), and the DGK or a control protein (800 ng) as described (Topham et
al., 1998). 48 h later, the cells were rapidly harvested and assayed for GTP-
Ras as described (Taylor and Shalloway, 1996). H-Ras was detected in the
pellets and lysates after SDS-PAGE using an antibody specific for H-Ras
or the myc tag (C-20 or 9E10; Santa Cruz Biotechnology, Inc.). GFP-Ras-
GRP was detected with monoclonal anti-GFP (CLONTECH Laboratories,
Inc.) and anti-HA (F-7; Santa Cruz Biotechnology, Inc.) was used to immu-
noblot the DGKs. To measure changes in GTP-Ras induced by kinase-
dead DGK
 
z
 
 in Jurkat cells, the cells were transfected as described above
and then, after addition of anti-CD3 (5 
 
m
 
g/ml, Diatek clone CRIS-7), GTP-
Ras was detected as described previously (Taylor and Shalloway, 1996).
 
Results
 
DGK
 
z
 
 and RasGRP Physically Associate in the Cell
 
We showed previously that DGK
 
z
 
 could regulate cell pro-
liferation by reducing DAG accumulation in the nucleus
(Topham et al., 1998). Since generation of DAG at the
plasma membrane also signals proliferation, and the ma-
jority of DGK
 
z
 
 is found outside of the nucleus (Topham et
al., 1998), we asked if DGK
 
z
 
 could also regulate growth-
promoting DAG signals at the plasma membrane. One
way that cells maintain the fidelity of signaling cascades is
to organize appropriate signaling proteins into a complex.
Such associations allow the activation of necessary effec-
tor molecules, while segregating them to avoid “cross-
talk” between signaling pathways (Pawson and Scott,
1997; Zuker and Ranganathan, 1999). Since RasGRP re-
quires DAG for its function, we considered the possibility
that DGK
 
z
 
 associates with RasGRP and regulates its ac-
tivity by locally metabolizing DAG.
To determine whether DGK
 
z
 
 and RasGRP could asso-
ciate with the same signaling complex, we cotransfected
HEK293 cells with cDNA constructs, encoding DGK
 
z
 
with a FLAG epitope tag at its COOH terminus (DGK
 
z
 
-
FLAG) and RasGRP with an NH
 
2
 
-terminal HA epitope
tag (HA-RasGRP). We immunoprecipitated DGK
 
z
 
 using
anti-FLAG and detected RasGRP by immunoblotting. In
these experiments, RasGRP coprecipitated with DGK
 
z
 
and their association was robust: 
 
.
 
20% of HA-RasGRP
coprecipitated (Fig. 1 a). Alternatively, when we immuno-
precipated RasGRP, DGK
 
z
 
 coprecipitated (not shown).
These experiments indicated that the two proteins associ-
ated with the same signaling complex. In additional exper-
iments we could not detect an interaction between DGK
 
z
 
and two other Ras GEFs, Sos1 and RasGRF1, indicating
that its association with RasGRP was selective (not
shown). By examining mutants of DGK
 
z
 
, we mapped a re-
gion near the COOH terminus of the catalytic domain that
substantially reduced coprecipitation (Fig. 1 b), indicating
that a motif in or near this region was necessary for DGK
 
z
 
to interact with the signaling complex.
To assess whether endogenous RasGRP and DGK
 
z
 
 as-
sociate with the same signaling complex, we used A172
cells, a glioblastoma cell line that we have shown to ex-
press DGK
 
z 
 
(Topham et al., 1998). We determined by
Western blotting that they also express RasGRP (Fig. 1 c)
and then asked whether DGK
 
z
 
 coimmunoprecipitated
with RasGRP. We found that RasGRP immunoprecipi-
tates had two times (
 
6
 
0.8; 
 
n 
 
5
 
 3) more DGK activity than
control immunoprecipitates where the antibody was prein-
cubated with its affinity peptide. Using another anti-Ras-
GRP antibody for the immunoprecipitation, we similarly
found 2.2 times (
 
6
 
1.7; 
 
n 
 
5
 
 4) more DGK activity in the
precipitates compared with control. These data suggested
that endogenous RasGRP and DGK
 
z
 
 interacted with the
same signaling complex in A172 cells. To determine if the
presence of DAG regulated their interaction, we com-
pared DGK activity in RasGRP immunoprecipitates from
control A172 cells to cells treated with a phorbol ester,
phorbol 12-myristate 13-acetate (PMA). We found in
these experiments that compared with untreated cells,
PMA almost doubled the amount of associated DGK ac-
tivity (1.9 
 
6
 
 0.7; 
 
n 
 
5
 
 3; Fig. 1 c). PMA did not enhance
RasGRP precipitation (Fig. 1 c), indicating that it in-
Figure 1. RasGRP coimmunoprecipitates with DGKz.
(a) DGKz with or without a FLAG epitope tag was
cotransfected into HEK293 cells along with HA-Ras-
GRP. 48 h later, anti-FLAG antibodies were used to
immunoprecipitate DGKz. Normal mouse IgG was
used as a control. After SDS-PAGE of the pellets or
10% of the lysates, RasGRP was detected by immuno-
blotting with anti-HA. The blot was then stripped and
reprobed for DGKz. (b) HA-RasGRP was transfected
along with a control vector or progressive COOH-ter-
minal truncations of DGKz containing FLAG epitope
tags. The DGK proteins were immunoprecipated with
anti-FLAG and then coimmunoprecipitation of HA-
RasGRP was detected by immunoblotting with poly-
clonal anti-HA. The blot was stripped and then the
DGKs were detected using anti-DGKz. The three
DGK constructs shown encode amino acids 1–748,
1–605, or 1–467 with FLAG epitope tags at their
COOH termini. (c) A172 cells, either control or treated with PMA (90 ng/ml, 30 min), were lysed
and then RasGRP was immunoprecipitated using an affinity purified antibody. To verify the speci-
ficity of the immunoprecipitation, the antibody was preincubated with its affinity peptide or a con-
trol peptide before the immunoprecipitation. The precipitates were then used either for Western
blotting to detect RasGRP (top) or for DGK activity assays (bottom). (d) RasGRP was immuno-
precipitated from control or PMA-treated A172 cells as described in the legend to c and then the
precipitates were used for Western blotting to detect coimmunoprecipitation of DGKz. 
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creased its association with DGK
 
z
 
. Supporting this, we
found by Western blotting that PMA treatment signifi-
cantly enhanced coprecipitation of DGK
 
z
 
 (Fig. 1 d). These
data demonstrate that endogenous DGK
 
z
 
 and RasGRP
interact and that their association is likely augmented in
the presence of DAG.
 
DGK
 
z
 
 and RasGRP Colocalize
 
As an independent test to determine if RasGRP and
DGK
 
z
 
 may interact in vivo, we assessed whether the en-
dogenous proteins colocalized in A172 cells. Consistent
with our previous observations, we found by indirect im-
munofluorescence and confocal microscopy that a fraction
of DGK
 
z
 
 was in the nucleus of the cells (not shown). We
also observed marked localization of DGK
 
z
 
 at the periph-
ery of cell extensions, regions that also costained strongly
for actin (Fig. 2 a). We found that the distribution of Ras-
GRP peripherally in actin-rich regions was very similar to
that of DGK
 
z 
 
(Fig. 2 a). This suggested that the two pro-
teins colocalized. Since both the anti-DGK
 
z
 
 and anti-Ras-
Figure 2. RasGRP and DGK colocalize. (a) A172 cells were immunostained for DGKz (top) or RasGRP (bottom). Phalloidin was
used to identify actin filaments. To assure that the immunostaining was specific, the antibodies were preincubated with their affinity
peptide before staining the cells. Several areas of intense staining common to actin and DGKz or RasGRP are indicated by the arrows.
(b) Cos-7 cells were cotransfected with GFP-RasGRP and DGKz. 24 h later, they were suspended and then allowed to spread for 30
min on glass slides coated with fibronectin. The cells were then immunostained to detect DGKz (red), nuclei were counterstained
(blue), and immunofluorescence images were obtained. (c) To view migrating cells, A172 cell monolayers were wounded with a pipet
tip 12 h before immunostaining. Using antibodies directly conjugated with separate fluorophores, the cells were immunostained to de-
tect RasGRP (green) and DGKz (red) and then viewed by confocal microscopy (Bio-Rad Laboratories), and digital images were ob-
tained. One representative cell is shown migrating into the wounded area, with arrows indicating overlapping localization that was also
apparent in most cells. The boxed area is magnified in the lower panels to demonstrate colocalization at the leading edge. Bars, 10 mm.Topham and Prescott DAG Kinase z Regulates RasGRP Activity 1139
GRP antibodies were produced in rabbits, it was difficult
to assess colocalization of the two proteins using indirect
immunofluorescence. To allow simultaneous detection of
both proteins, we cotransfected Cos-7 cells with GFP-Ras-
GRP and DGKz and then immunostained the cells to as-
sess localization of the overexpressed proteins. To aug-
ment cell spreading, we allowed them to spread on a
surface coated with fibronectin and then immunostained
for DGKz. When overexpressed, both proteins distributed
throughout the cytoplasm and nucleus. But, consistent
with the A172 cell immunostaining, both proteins also lo-
calized at the leading edge of spreading cells (Fig. 2 b). As
overexpression of proteins can lead to aberrant localiza-
tion, we directly labeled the two antibodies with separate
fluorophores, which allowed simultaneous detection of en-
dogenous DGKz and RasGRP in A172 cells. Using confo-
cal microscopy, we observed that DGKz and RasGRP ex-
tensively colocalized, most dramatically at cell extensions
peripherally and at the leading edge of migrating cells
(Fig. 2 c). These results, coupled with our immunoprecipi-
tation data, strongly indicated that DGKz and RasGRP
associate with the same signaling complex in vivo.
DGKz Binds Selectively to A15-H-Ras
Ras GEFs promote the release of GDP from Ras and fa-
cilitate GTP binding. Inactive, mutant Ras proteins, like
A15-Ras are thought to exert dominant negative effects
because they have a high affinity for Ras GEFs and se-
quester them from endogenous Ras proteins (Feig, 1999).
Consistent with this, we found that RasGRP coprecipi-
tated with A15-Ras, so we hypothesized that DGKz would
also associate with A15-Ras. To test this, we cotransfected
HEK293 cells with DGKz-FLAG and A15-Ras and then
immunoprecipitated DGKz. We found that A15-Ras co-
precipitated with DGKz and that the interaction was ro-
bust: .20% of the total A15-Ras coprecipitated (Fig. 3 a).
We also observed the converse: immunoprecipitates of
A15-Ras had DGKz activity (not shown). Further, when
all three proteins, A15-Ras, RasGRP, and DGKz, were in-
cluded in the transfection, both RasGRP and A15-Ras co-
precipitated with DGKz (not shown), indicating that they
associated with the same signaling complex.
V12-Ras is a constitutively active mutant that, unlike
A15-Ras, has a very low affinity for Ras GEFs (Feig,
1999). We tested its affinity for DGKz and found that,
compared with A15-Ras, it had a very low affinity for
DGKz, even though cell lysates had substantially more
V12-Ras (Fig. 3 b). These results indicated that DGKz
preferred to associate with signaling complexes containing
inactive Ras. To test whether there is direct binding be-
tween H-Ras and DGKz, we incubated recombinant pro-
teins in vitro and found that DGKz coprecipitated both
GDP- and GTP-bound H-Ras with equal efficiency (not
shown). DGKz’s indifference in vitro for GTP-Ras versus
GDP-Ras, but preference in vivo for A15-Ras, seemed
contradictory. To further probe this issue, we tested the in
vivo affinity of DGKz for wild-type H-Ras, which predom-
inantly binds GDP (Malumbres and Pellicer, 1998; Vojtek
and Der, 1998). We found by coimmunoprecipitation that
DGKz’s affinity for wild-type H-Ras was similar to its af-
finity for V12-Ras and much less than that for A15-Ras
Figure 3. DGKz and A15-Ras
coimmunoprecipitate. (a) DGKz
with or without a FLAG epitope
tag was cotransfected into
HEK293 cells along with A15-
Ras. 48 h later, anti-FLAG anti-
bodies were used to immunopre-
cipitate DGKz. Normal mouse
IgG was used as a control. After
SDS-PAGE of the pellets or
10% of the lysates, A15-Ras was
detected by immunoblotting
with anti–H-Ras. The blot was
then stripped and reprobed for
DGKz. (b) DGKz-FLAG or a
control vector was transfected
into Cos-7 cells with H-Ras mu-
tants: either V12-Ras or A15-
Ras. After 48 h, anti-FLAG was
used to immunoprecipitate
DGKz. After SDS-PAGE of
both the lysates and pellets,
H-Ras or DGKz was detected
with specific antibodies.
Figure 4. DGKz attenuates RasGRP activity. (a) HEK293 cells
were transfected with myc-Ras and either GFP or GFP-RasGRP
along with DGKz or a kinase-dead, mutant DGKz (DATP). After
48 h, GTP-Ras was affinity-precipitated (Taylor and Shalloway,
1996) and then detected by immunoblotting. GFP-RasGRP pro-
tein expression was not altered by the DGKs (not shown). (b) Myc-
Ras was transfected into HEK293 cells along with GFP or GFP-
RasGRP and a control vector or a DGK isotype (b, g, d, e, z, or i)
with an NH2-terminal HA epitope tag. After 48 h, GTP-Ras was
affinity-precipitated and then detected by immunoblotting. Ras-
GRP, DGK, and H-Ras were detected in the cell lysates by immu-
noblotting with anti-GFP, anti-HA, or anti-H-Ras. (c) DGKz or an
alternatively spliced variant (z2) was transfected into HEK293 cells
along with GFP or GFP-RasGRP and the luciferase reporter vec-
tors. 48 h later, the cells were harvested and luciferase activity,
DGK activity, and cellular DAG were determined in triplicate.
These values were normalized to either b-galactosidase activity (lu-
ciferase), lipid phosphate (DAG), or total protein (DGK activity).
Expression levels of the two DGKs were similar (not shown).The Journal of Cell Biology, Volume 152, 2001 1140
(not shown). Its preferential association with mutant, inac-
tive H-Ras proteins, which sequester Ras GEFs, suggests
that DGKz does not distinguish between GTP- or GDP-
Ras in vivo, but instead prefers to associate with signaling
complexes enriched in Ras GEFs. Consistent with this, the
in vitro binding affinity between recombinant DGKz and
H-Ras was much less than the affinity in vivo between
DGKz and A15-Ras. So, although DGKz appears to phys-
ically, but weakly, bind H-Ras, it prefers to associate with
the signaling complex, probably by binding to other pro-
teins in the complex.
DGKz Regulates RasGRP Activity
RasGRP has a DAG-responsive C1 domain that is neces-
sary for its transforming activity (Ebinu et al., 1998; Tog-
non et al., 1998). We reasoned that DGKz associated with
a signaling complex containing H-Ras and RasGRP to
regulate the local DAG concentration and thus control
Ras activity by regulating RasGRP. We first verified that
RasGRP required its C1 domain for activity. Using an
Elk-1 luciferase reporter (Kawasaki et al., 1998), we found
that deleting this C1 domain, or mutating a crucial cysteine
within it, rendered RasGRP inactive (not shown), indicat-
ing that this motif was required for its activity. To test
whether DGKz could regulate RasGRP, we cotransfected
H-Ras with a myc epitope tag (myc-Ras) along with Ras-
GRP and wild-type DGKz or mutant, kinase-dead DGKz
into HEK293 cells and then measured GTP-Ras by affin-
ity precipitation (Taylor and Shalloway, 1996). In these ex-
periments, we found that expression of DGKz significantly
attenuated Ras activation induced by RasGRP (Fig. 4 a).
DGK activity was required for the inhibition: the kinase-
dead DGKz ( DATP, G355D; Topham et al., 1998) af-
fected Ras activation minimally (Fig. 4 a), even though its
protein expression level was similar to wild-type DGKz
and it still coprecipitated RasGRP with equal efficiency
(not shown).
Regulation of RasGRP by DGKz Is Spatially Discrete
The regulation of RasGRP by DGKz is compatible with
their patterns of tissue expression: both RasGRP and
DGKz mRNA are highly expressed in brain and hemato-
poietic organs. However, DGK isotypes exhibit significant
overlap in their expression patterns. In fact, one cell will of-
ten express two or three different DGK isotypes, often
from different DGK subfamilies (Topham and Prescott,
1999). This suggests that like the PKCs and other large
families of signaling enzymes, DGK isotypes have distinct
cellular functions. We wondered whether inhibition of Ras-
GRP by DGKz was due to wholesale metabolism of DAG
or if it resulted from selective inhibition by DGKz and not
other DGKs. We tested six different DGK isotypes (b, g, d,
e, z, and i) for inhibition by cotransfecting them with myc-
Ras and RasGRP; we then used affinity precipitation to de-
tect GTP-Ras. Each of the DGKs had an NH2-terminal
HA epitope tag, so their protein expression levels were di-
rectly comparable by Western blotting. Although most of
the isotypes have significantly higher expression than
DGKz, only DGKz significantly attenuated RasGRP activ-
ity (Fig. 4 b). Comparing in vivo DGK activity is not possi-
ble, and it is not clear whether in vitro DGK activity assays
accurately reflect in vivo activity. But, using an in vitro as-
say system incorporating ideal conditions for most of the
tested DGK isotypes, we found that activity levels roughly
correlated with their protein expression levels in several ex-
periments (not shown). In fact, DGKe often had four to
five times more in vitro activity and protein expression than
DGKz, but consistently increased RasGRP activity. Fur-
ther, a DAG lipase (human lysosomal acid lipase), which
metabolizes DAG by a different mechanism, did not signif-
icantly inhibit RasGRP activity (not shown). These results
indicate that the inhibition of RasGRP could not be repro-
duced by globally manipulating cellular DAG levels and
that the inhibition by DGKz must be spatially discrete.
The DGKz gene has two splice variants (Ding et al.,
1997). The one we tested is the more common and widely
expressed form. Alternative splicing, predominantly in
Figure 5. DGKz inhibits RasGRP at the level of Ras activation.
Elk-1 activity was detected by a luciferase reporter (Stratagene).
In all cases, luciferase activity in the cell lysates was determined
in triplicate and normalized to b-galactosidase activity, which was
included in the transfection. (a) HEK293 cells were transfected
with GFP or GFP-RasGRP. 16 h later, a PKC inhibitor (PKCi;
100 nM Ro-32-0432) or control vehicle was added. After 20 min,
PMA (0.5 ng/ml) was added for 24 h and then luciferase and
b-galactosidase activities in the cell lysates were determined.
Shown are the mean and standard deviation. (b) HEK293 cells
were transfected with GFP or GFP-RasGRP along with a control
vector or DGKz. 16 h later, one of two PKC inhibitors (a, 200 nM
Ro-31-7549; b, 100 nM Ro-32-0432) or control vehicle was added.
After 24 h, the cells were harvested and luciferase and b-galac-
tosidase activities in the cell lysates were determined. (c) Raf:ER
or a control vector was transfected into HEK293 cells along with
DGKz, DATP, or a control vector. 24 h later, estrogen (1 mM) or
control vehicle was added for 10 h. The cells were harvested and
luciferase and b-galactosidase activities in the cell lysates were
determined. (d) Jurkat cells were transfected by electroporation
with myc-Ras and either GFP or kinase-dead DGKz (DATP). 48 h
later, TCR signaling was activated with anti-CD3 (5 mg/ml,
CRIS-7) for up to 4 h. GTP-Ras was affinity-precipitated and
then detected by immunoblotting.Topham and Prescott DAG Kinase z Regulates RasGRP Activity 1141
muscle tissue, results in a protein (z2) where the initial 54
amino acids are replaced with a 262–amino acid fragment.
The alternative splicing appears to alter the subcellular lo-
calization of z2 (Topham, M.K., manuscript in prepara-
tion) and does not affect in vitro activity levels. Thus, z2
offered a unique opportunity to test whether the inhibition
of RasGRP was spatially discrete and selective. Using ei-
ther affinity precipitation of GTP-Ras or the Elk-1 lu-
ciferase system, we found that z2 did not significantly in-
hibit RasGRP (Fig. 4 c), whereas the more common splice
variant of DGKz did. Protein expression levels of the
splice variants were virtually identical in these experi-
ments as judged by Western blotting using a specific anti-
body that recognizes both proteins (not shown). This lack
of inhibition by z2 was not owing to differences in DGK
activity: both proteins had similar in vitro activity levels
(Fig. 4 c). We considered the possibility that the more
common DGKz inhibited RasGRP because it more effi-
ciently metabolized total cellular DAG. However, we
found similar total DAG levels in the cell homogenates
(Fig. 4 C). This discrepancy, differential inhibition of Ras-
GRP but similar total DAG levels, likely reflects techni-
cal constraints of the DAG assay. It detects only global
cellular DAG. Quantitatively measuring precise, spatial
changes in DAG accessible to the RasGRP signaling com-
plex is not technically possible. However, we believe that
our assays measuring active Ras indirectly detect these fo-
cal changes. We conclude that DGKz selectively inhibits
RasGRP by a spatially discrete mechanism.
Inhibition of RasGRP Activity Occurs at the Level of 
Ras Activation
We observed that a mutant, kinase-dead DGKz did not in-
hibit RasGRP, indicating that DGK activity was required
for the inhibition and suggesting that this occurred
through localized metabolism of DAG. To assure that the
inhibition of Ras activity that we observed resulted from
metabolism of DAG by DGKz, we reasoned that DGKz
would not affect RasGRP activity induced by phorbol es-
ters, which act as DAG analogues but cannot be metabo-
lized by DGKs. We verified with the Elk-1 luciferase sys-
tem that PMA, a phorbol ester, increased RasGRP
activity. This activation was not reduced by PKC inhibitors
(Fig. 5 a), which demonstrated that the PMA was likely ac-
tivating RasGRP. Supporting our hypothesis that DGKz
inhibits RasGRP by metabolizing DAG, DGKz abolished
RasGRP activity in the absence of PMA, but did not in-
hibit PMA-induced RasGRP activity (Fig. 5 a).
Activation of PKC isoforms can initiate mitogen-acti-
vated protein kinase signaling, but the precise mechanism
of activation of the cascade is not clear (Marais et al.,
1998). Since the PKC family is the largest group of pro-
teins allosterically activated by DAG (Newton, 1997; Ron
and Kazanietz, 1999), we considered the possibility that
our assay systems may have measured inhibition of PKC
activity rather than that of RasGRP. To assure that we
were not measuring an effect on PKC activity, we deter-
mined whether PKC inhibitors reduced Elk-1 luciferase
activity induced by RasGRP. We found that two different
PKC inhibitors, well above their IC50, did not inhibit Elk-1
luciferase activity induced by RasGRP (Fig. 5 b), indicat-
ing that the inhibition by DGKz was mediated through
RasGRP, rather than PKC.
As an additional test to assure that the level of inhibi-
tion by DGKz occurred at RasGRP, we reasoned that
DGKz would not affect mitogen-activated protein kinase
activation initiated downstream of Ras. To activate this
signaling cascade without affecting Ras, we used a chi-
meric cDNA consisting of the hormone-binding domain of
the estrogen receptor fused to an oncogenic form of Raf-1
(Samuels et al., 1993). The chimeric protein is active only
in the presence of exogenous estrogen and its activation
does not require Ras. We found that DGKz did not affect
Elk-1 luciferase activity induced by this construct (Fig. 5
c). Consistent with this, we also observed that DGKz did
not significantly inhibit luciferase activity induced by con-
stitutively active forms of H-Ras (V12-Ras) or MEK1 (not
shown). These data demonstrate that DGKz inhibits Ras-
GRP rather than affecting a downstream event.
Kinase-dead DGKz Prolongs Ras Signaling in
Jurkat Cells
RasGRP is known to activate Ras and DAG is required
for its activity. However, little is known of the physiologi-
cal contexts in which this activation occurs. Ebinu et al.
(2000) recently demonstrated that RasGRP is, in part, re-
sponsible for activating Ras after TCR ligation. A conse-
quence of this event is cellular proliferation. It is not sur-
prising then that Li et al. identified RasGRP as a potential
leukemia disease gene by assaying murine leukemia cell
DNA for common sites of retroviral integration (Li et al.,
1999). Together, these observations demonstrate that Ras-
GRP signals cell proliferation and that its activity must be
exquisitely controlled to avoid an abnormal growth re-
sponse. Our data demonstrate that when both DGKz and
RasGRP are overexpressed, the DGK attenuates Ras-
GRP activity. For the endogenous proteins, this is likely a
mechanism to terminate Ras signaling. Overexpression of
inactive, mutant proteins can interfere with the physiologi-
cal function of their endogenous, wild-type counterparts.
So, to test if endogenous DGKz regulates RasGRP, we de-
termined whether overexpression of mutant, kinase-dead
DGKz affected Ras activation. In Jurkat cells, RasGRP
signaling is initiated after activation of the TCR (Ebinu et
al., 2000), and DGKz is expressed in these cells (not
shown). To test if kinase-dead DGKz altered Ras signal-
ing, we overexpressed it along with myc-Ras in Jurkat cells
and then activated the TCR with an antibody for up to 4 h.
Using GTP-Ras affinity precipitation, we consistently ob-
served slightly higher basal GTP-Ras in cells overexpress-
ing kinase-dead DGKz. After activation of the TCR, we
found in control cells that GTP-Ras peaked between 5 and
10 min and then gradually declined to basal levels by 1 h.
Conversely, in cells expressing kinase-dead DGKz, GTP-
Ras peaked for up to 20 min and then gradually declined,
but did not reach basal levels for .2 h. The kinase-dead
DGKz likely prolonged Ras activation by interfering with
the function of endogenous DGKz. We conclude that in
Jurkat cells, endogenous DGKz facilitates termination of
TCR signaling by regulating the activity of RasGRP.
Discussion
Our observations support a novel mechanism of localized
regulation of RasGRP by DGKz. We found evidence that
these proteins interacted using immunoprecipitations andThe Journal of Cell Biology, Volume 152, 2001 1142
we observed that they colocalized in a glioblastoma cell
line. Interestingly, their localization was at the leading
edge of migrating cells, an area of intense actin remodel-
ing. The specific function of RasGRP in this region is not
clear, but Ras activity has an integral role in cell motility
(Nobes and Hall, 1999). Thus, we have demonstrated that
DGKz inhibits RasGRP and that this is a highly localized
event. The most direct evidence supporting this regulation
as precise and spatial is the lack of inhibition by z2, the al-
ternatively spliced DGKz isoform. This variant differs
only at the NH2 terminus (Ding et al., 1997). The alterna-
tive splicing appears to predominantly affect subcellular
distribution, which likely reduces or abolishes its interac-
tion with the RasGRP signaling complex and eliminates
the inhibition. Also supporting the selectivity of the inhibi-
tion, five other DGK isotypes failed to inhibit RasGRP, as
did a DAG lipase, which metabolizes DAG by a different
mechanism. The specificity exhibited by DGKz, coupled
with our immunoprecipitation and immunofluorescence
data, strongly indicates that H-Ras, RasGRP, and DGKz
are spatially organized in a regulated signaling complex.
DGK Activity May Inhibit Cell Transformation
Ras activity must be precisely regulated or abnormal cellu-
lar proliferation can occur. Supporting this, an estimated
30% of human tumors have an activating mutation of Ras
(Vojtek and Der, 1998), and oncogenic Ras is an essential
component of tumor maintenance (Chin et al., 1999). Li et
al. (1999), using large-scale mutagenesis, noted that Ras-
GRP was a potential leukemia disease gene and overex-
pression of RasGRP in cultured cells induced a trans-
formed phenotype (Ebinu et al., 1998; Tognon et al.,
1998). Combined, these observations indicate that abnor-
mally high RasGRP activity can lead to malignant trans-
formation. So, conditions of excess DAG signaling may
contribute to malignant changes by abnormally activating
RasGRP. Supporting this mechanism, overexpression of
PLCg1, which causes excess DAG, induced a malignant
phenotype (Chang et al., 1997) and PLCg1 was a neces-
sary component of growth factor–induced mitogenesis
(Wang et al., 1998). Several groups have also reported that
oncogene-transformed cells have a higher DAG content
(Preiss et al., 1986; Wolfman and Macara, 1987; Kato et al.,
1988). Historically, activation of the PKCs was considered
responsible for the malignant changes induced by DAG,
but RasGRP may contribute as well. Like high PLC activ-
ity, abnormally low DGKz activity could cause inappropri-
ate DAG signaling, leading to malignant changes by acti-
vating RasGRP. Indeed, we demonstrated that expression
of inactive DGKz in Jurkat cells prolonged Ras activation
after TCR ligation. Thus, by attenuating the DAG pool
necessary to maintain RasGRP activity, DGKz may have a
pivotal role in modulating Ras signaling in some contexts.
Advantages to Formation of a Signaling Complex
Associating with a DGK offers RasGRP three potential
advantages in regulating signals. First, DGK activity allows
the signal to activate RasGRP to be more spatially precise,
because both the production (PLC) and inactivation
(DGK) of DAG are controlled in the same location. Sec-
ond, since the DGK regulates DAG independently of PLC,
it offers a safety mechanism to reduce RasGRP activity in
cases of abnormally high PLC activity. Third, formation of
a signaling complex offers a kinetic advantage. Signaling
events mediated through low molecular weight GTP-bind-
ing proteins like Ras and G proteins are generally short-
lived to allow for rapid subsequent reactivation. Rapid on/
off cycling is achieved by associating the GTP-binding pro-
tein with its GTPase-activating proteins (GAPs) and GEFs.
For example, Ross (1995) pointed out that by associating
regulatory proteins that have opposing enzymatic activities
(GAPs and GEFs) with the protein that they regulate
(Ras), high velocity cycling of the signal can be achieved
because dissociation and reassociation of the complex are
not necessary. DGKz likely contributes to this mechanism
by allowing rapid cycling of the activity of RasGRP. Ex-
tending this paradigm, RasGRP may be similarly regulated
by associating with both a PLC (GEF) and a DGK (GAP).
DGKs May Have Diverse Roles in Signaling Complexes
Local regulation of DAG signaling by DGK isozymes may
be a generalized mechanism to regulate DAG-activated
proteins. Supporting this, van der Bend et al. (1994) dem-
onstrated that DGK activity was restricted to DAG gener-
ated upon receptor activation, rather than upon nonspe-
cific, global DAG production, and there are multiple
reports of increased DGK activity after receptor activation
(Topham and Prescott, 1999). A more direct example was
published recently by two groups who found in Caenorhab-
ditis elegans that DGK-1, which is most similar to human
DGKu, negatively regulated synaptic transmission (Miller
et al., 1999; Nurrish et al., 1999). It likely accomplished this
regulation by metabolizing DAG that would otherwise ac-
tivate Unc-13, a protein that participates in neurotransmit-
ter secretion. This model supports our paradigm for DGK
function: spatial regulation of proteins activated by DAG.
Indicating a general role for DGKs as integral partners
in signaling complexes, Houssa et al. (1999) found that
DGKu associated with a complex containing RhoA, and
Tolias et al. (1998) observed DGK activity in Rac1 signal-
ing complexes. Interestingly, Tolias et al. (1998) also found
phosphatidylinositol 5-kinase activity in the Rac1 complex.
Phosphatidylinositol 5-kinases are dramatically activated
by PA, the product of the DGK reaction, suggesting that
DGKs resident in signaling complexes may also activate
proteins by generating PA. Based on our data, it is likely
that each DGK isoform has the specific function of regulat-
ing one or a few lipid-activated proteins by locally metabo-
lizing DAG or by generating PA. As both DAG and PA
can regulate the activity of several families of enzymes (Ka-
wasaki et al., 1998; Ron and Kazanietz, 1999), DGKs likely
function quite broadly. It appears that the DGKs do not
simply perform the mundane task of converting DAG to
PA for subsequent regeneration of phosphatidylinositols,
but likely function as integral members of elegantly regu-
lated signaling complexes. Thus, it may be possible to affect
downstream signaling events by altering DGK activity.
Conclusions
We observed that DGK activity terminated RasGRP acti-
vation and that only one DGK isoform, DGKz, could in-
hibit. Even an alternatively spliced DGKz isoform did notTopham and Prescott DAG Kinase z Regulates RasGRP Activity 1143
significantly affect RasGRP activity, demonstrating the
specificity of this regulation. Furthermore, we found that
endogenous DGKz and RasGRP colocalized in A172
cells, indicating that they likely associate with the same
signaling complex. Supporting this, we demonstrated that
DGKz and RasGRP coimmunoprecipitated and that de-
leting a region within the catalytic domain of DGKz elimi-
nated their interaction. Phorbol esters, which are DAG
analogues that cannot be metabolized by DGKs, enhanced
the interaction between DGKz and RasGRP, suggesting
that their interaction was facilitated in the presence of
DAG. DGKz also selectively coimmunoprecipitated with
a mutant H-Ras protein, A15-Ras, that binds strongly to
Ras GEFs. This suggests a model where the activity of
RasGRP, and consequently Ras, is exquisitely regulated
by the coordinated activity of PLCg1, which generates
DAG, and DGKz, which terminates the signal (Fig. 6).
This may be a common mechanism to spatially regulate
DAG and perhaps other lipid signals.
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Figure 6. Proposed mechanism for precise regulation of RasGRP
activity. After TCR stimulation, PLCg1 is activated and initiates
DAG signaling. One protein activated by the DAG is RasGRP.
DAG accumulation also recruits DGKz to the RasGRP signaling
complex, where it attenuates RasGRP activity by converting the
DAG to PA.